Violich Capital Management Inc. Takes Position in Eli Lilly and Company $LLY

Key Points

• Violich Capital Management opened a new position in Eli Lilly during the fourth quarter, buying 1,446 shares valued at about $1.55 million. Institutional investors still own a large majority of the stock, at 82.53%.
• Recent commentary around Lilly remains mostly positive, with analysts raising price targets and reports highlighting strong demand for GLP-1 drugs like Mounjaro and promising early data for weight-loss pills that could expand the market beyond injections.
• Lilly continues to report strong fundamentals, posting $8.55 EPS on $19.8 billion in quarterly revenue, while also announcing an additional $4.5 billion investment in Indiana manufacturing sites to support future production.

Violich Capital Management Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,446 shares of the company's stock, valued at approximately $1,554,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the fourth quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after buying an additional 16 shares during the last quarter. 10Elms LLP increased its holdings in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares during the last quarter. Miller Global Investments LLC acquired a new position in Eli Lilly and Company in the fourth quarter worth approximately $33,000. Finally, Hopwood Financial Services Inc. increased its holdings in Eli Lilly and Company by 113.6% in the third quarter. Hopwood Financial Services Inc. now owns 47 shares of the company's stock worth $36,000 after buying an additional 25 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term value despite the target still sitting below the recent share price. MarketScreener
• Positive Sentiment: Multiple reports highlighted strong demand for Lilly’s GLP-1 medicines, including Mounjaro, with first-quarter sales described as a major driver of revenue growth and a key reason investors remain optimistic about future earnings. Motley Fool
• Positive Sentiment: Reuters reported that early weight-loss pill data is boosting Lilly and Novo Nordisk by raising hopes the market could expand beyond injections to millions more patients, which could support a larger long-term revenue opportunity. Reuters
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, reinforcing confidence in its ability to meet future demand for weight-loss and other therapies while expanding U.S. production capacity. Benzinga
• Neutral Sentiment: Several commentary pieces continued to frame Lilly as a high-quality growth stock, but these were largely reiterations of the bullish long-term thesis rather than fresh catalysts. Zacks
• Neutral Sentiment: Articles about shareholder support for the board and broader analyst upgrades suggest stable governance and sentiment, but they do not appear to be major standalone trading catalysts. TipRanks
• Negative Sentiment: One article noted that Eli Lilly’s valuation remains rich and that some investors see more upside in competitors, which can limit enthusiasm even when fundamentals are strong. Motley Fool

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Weiss Ratings upgraded Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a report on Monday, May 4th. Zacks Research downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Friday, January 30th. Sanford C. Bernstein restated an "outperform" rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. BMO Capital Markets reiterated an "outperform" rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $1,285.00 price target on shares of Eli Lilly and Company in a report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $1,218.33.

Eli Lilly and Company Trading Down 2.8%

Shares of LLY stock opened at $948.01 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business's 50 day moving average is $943.90 and its two-hundred day moving average is $990.90. The company has a market cap of $892.78 billion, a PE ratio of 33.68, a price-to-earnings-growth ratio of 1.04 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.